Calypso tumor tracking technology granted clearance

TriMed Staff | | Health Imaging | Oncology Imaging
Calypso Medical Technologies has received FDA clearance for its Calypso System, a technology that automates response to organ motion occurring during radiation delivery to prostate cancer tumors. 

The system, which includes Dynamic Edge Gating Technology, utilizes miniature implanted transponders to provide information on the location of the tumor during external beam radiation therapy and may decrease in the side effects associated with prostate radiotherapy, stated the Seattle-based company.

TriMed Staff

Related Content

MRI guidance significantly reduces radiotherapy side effects compared to CT
Interventional procedure often as effective as surgery for difficult-to-treat liver cancer
AI tumor volume estimations could improve prostate cancer treatment strategies
MRI could be 'powerful tool' for guiding surgery decisions in patients with rectal cancer
Breast cancer only visible via MRI is often less aggressive
Breast cancer rates are on the rise, new report reveals

Around the web

Radiology Business
Key Medicare reimbursement and No Surprises Act updates from RSNA 2024

Richard Heller III, MD, RSNA board member and senior VP of policy at Radiology Partners, offers an overview of policies in Congress that are directly impacting imaging.
 

Cardiovascular Business
Philips, Mayo Clinic using AI to improve cardiac MRI technology

The two companies aim to improve patient access to high-quality MRI scans by combining their artificial intelligence capabilities.

Cardiovascular Business
Positron partners with Upbeat Cardiology Solutions to improve cardiac PET/CT access

Positron, a New York-based nuclear imaging company, will now provide Upbeat Cardiology Solutions with advanced PET/CT systems and services.